On the public citation graph

Herceptin acts as an anti-angiogenic cocktail

https://doi.org/10.1038/416279b
0 signed · 587 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1016/s0092-8674(00)81731-6openalex-snapshot
Tumor Induction of VEGF Promoter Activity in Stromal Cells
inferredcites →https://doi.org/10.1016/s0959-8049(00)00092-7openalex-snapshot
‘Accidental’ anti-angiogenic drugs
inferredcites →https://doi.org/10.1038/35052073openalex-snapshot
Untangling the ErbB signalling network
inferredcites →https://doi.org/10.1038/nm0901-987openalex-snapshot
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
inferredcites →https://doi.org/10.1038/scientificamerican1201-38openalex-snapshot
Vessels of Death or Life
inferredcites →https://doi.org/10.1056/nejm200103153441101openalex-snapshot
Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
inferredcites →https://doi.org/10.1074/jbc.271.47.30290openalex-snapshot
Post-transcriptional Control Regulates Transforming Growth Factor α in the Human Carcinoma KB Cell Line
inferredcites →https://doi.org/10.1093/jnci/93.14.1040openalex-snapshot
Angiogenic Heterogeneity: Regulation of Neoplastic Angiogenesis by the Organ Microenvironment
inferredcites →https://doi.org/10.1126/science.286.5449.2511openalex-snapshot
Leakage-Resistant Blood Vessels in Mice Transgenically Overexpressing Angiopoietin-1
inferredcites →https://doi.org/10.1172/jci12749openalex-snapshot
Thrombospondins as matricellular modulators of cell function
inferredcites →https://doi.org/10.1200/jco.2000.18.11.2201openalex-snapshot
c-erbB-2 Is of Independent Prognostic Relevance in Gastric Cancer and Is Associated With the Expression of Tumor-Associated Protease Systems

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.5281/zenodo.810572openalex-extracted
Life After Trastuzumab: Neu Strategies For Her2-Positive Breast Cancer
inferred← citeshttps://doi.org/10.1002/9780470485408.ch31openalex-snapshot
Therapeutic Antibodies in Clinical Use and Leading Clinical Candidates
inferred← citeshttps://doi.org/10.1002/9780470571224.pse551openalex-snapshot
Tumor Effect‐Site Pharmacokinetics: Mechanisms and Impact on Efficacy
inferred← citeshttps://doi.org/10.1002/9781118229019.ch3openalex-snapshot
Antibody‐Mediated Drug Delivery Systems for Breast Cancer Therapeutics
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm017openalex-snapshot
Tumor Angiogenesis
inferred← citeshttps://doi.org/10.1002/9781119000822.hfcm017.pub2openalex-snapshot
Tumor Angiogenesis
inferred← citeshttps://doi.org/10.1002/cai2.70035openalex-snapshot
Metronomic Chemotherapy in Breast Cancer: Unleashing the Potential of Combination Regimens
inferred← citeshttps://doi.org/10.1002/cncr.11656openalex-snapshot
Combined trastuzumab and paclitaxel treatment better inhibits ErbB‐2‐mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone
inferred← citeshttps://doi.org/10.1002/cncr.25399openalex-snapshot
Biologic and immunologic effects of preoperative trastuzumab for ductal carcinoma in situ of the breast
inferred← citeshttps://doi.org/10.1002/ijc.20798openalex-snapshot
Identification and validation of novel ERBB2 (HER2, NEU) targets including genes involved in angiogenesis
inferred← citeshttps://doi.org/10.1002/ijc.25026openalex-snapshot
Tumor angiogenesis and novel antiangiogenic strategies
inferred← citeshttps://doi.org/10.1002/jbio.201800379openalex-snapshot
Diffuse and nonlinear imaging of multiscale vascular parameters for in vivo monitoring of preclinical mammary tumors
inferred← citeshttps://doi.org/10.1002/jcb.21187openalex-snapshot
Tumor microenvironment abnormalities: Causes, consequences, and strategies to normalize
inferred← citeshttps://doi.org/10.1002/jcp.20387openalex-snapshot
HER‐2: A biomarker at the crossroads of breast cancer immunotherapy and molecular medicine
inferred← citeshttps://doi.org/10.1002/jcp.21260openalex-snapshot
The role of the EGFR signaling in tumor microenvironment
inferred← citeshttps://doi.org/10.1002/med.21345openalex-snapshot
Biomedical Applications of Trastuzumab: As a Therapeutic Agent and a Targeting Ligand
inferred← citeshttps://doi.org/10.1002/med.21452openalex-snapshot
Tumor angiogenesis revisited: Regulators and clinical implications
inferred← citeshttps://doi.org/10.1002/mrm.24815openalex-snapshot
Dynamic gadobutrol-enhanced MRI predicts early response to antivascular but not to antiproliferation therapy in a mouse xenograft model
inferred← citeshttps://doi.org/10.1002/msj.20220openalex-snapshot
Targeted Inhibition of Kinases in Cancer Therapy
inferred← citeshttps://doi.org/10.1002/path.1473openalex-snapshot
Are tumours angiogenesis‐dependent?
inferred← citeshttps://doi.org/10.1002/zamm.201700270openalex-snapshot
Stress alleviation strategy in cancer treatment: Insights from a mathematical model
inferred← citeshttps://doi.org/10.1007/0-387-23695-3_8openalex-snapshot
Growth Factors, Receptors, and Kinases: Their Exploration to Target Cancer
inferred← citeshttps://doi.org/10.1007/1-4020-3414-8_2openalex-snapshot
Role of Microenvironment on Gene Expression, Angiogenesis and Microvascular Function in Tumors
inferred← citeshttps://doi.org/10.1007/978-0-387-71518-6_24openalex-snapshot
Normalization of Tumor Vasculature and Microenvironment
inferred← citeshttps://doi.org/10.1007/978-1-4419-0131-6_1openalex-snapshot
Tumor Microvasculature and Microenvironment: Therapeutic Targets for Inhibition of Tumor Angiogenesis and Metastasis
inferred← citeshttps://doi.org/10.1007/978-1-4419-6744-2_8openalex-snapshot
Radiation Biology of Tumor and Normal Tissues
inferred← citeshttps://doi.org/10.1007/978-1-4419-8877-5_6openalex-snapshot
Monoclonal and Bispecific Antibodies in Combination with Radiotherapy for Cancer Treatment
inferred← citeshttps://doi.org/10.1007/978-1-4614-0052-3_8openalex-snapshot
Blood Flow and Tumour-Induced Angiogenesis: Dynamically Adapting Vascular Networks
inferred← citeshttps://doi.org/10.1007/978-1-4614-3685-0_28openalex-snapshot
Metastasis Initiation
inferred← citeshttps://doi.org/10.1007/978-1-4614-6528-7_17openalex-snapshot
Antibody-Mediated Receptor Endocytosis: Harnessing the Cellular Machinery to Combat Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4615-0081-0_21openalex-snapshot
Mechanism of Action of Anti-Her2 Monoclonal Antibodies: Scientific Update on Trastuzumab and 2c4
inferred← citeshttps://doi.org/10.1007/978-1-4939-1145-5_25openalex-snapshot
Adjuvant Biologic Agents for Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-1-4939-2047-1_3openalex-snapshot
Pharmacology and Clinical Development of New Molecularly Targeted Agents
inferred← citeshttps://doi.org/10.1007/978-1-4939-3801-8_6openalex-snapshot
Measuring Vascular Permeability In Vivo
inferred← citeshttps://doi.org/10.1007/978-1-59259-313-2_10openalex-snapshot
Oncogenes and Tumor Angiogenesis
inferred← citeshttps://doi.org/10.1007/978-1-59745-184-0_15openalex-snapshot
Normalization of Tumor Vasculature and Microenvironment
inferred← citeshttps://doi.org/10.1007/978-1-59745-337-0_14openalex-snapshot
Targeted Therapy For Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-1-60761-262-9_9openalex-snapshot
Targeted Therapy in Hematologic Malignancies
inferred← citeshttps://doi.org/10.1007/978-1-907673-94-8_5openalex-snapshot
HER2-Positive Metastatic Breast Cancer: Second-Line Treatment
inferred← citeshttps://doi.org/10.1007/978-3-030-21477-7_7openalex-snapshot
Novel Therapies to Overcome HER2 Therapy Resistance in Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-0346-0094-1_2openalex-snapshot
Trastuzumab as Adjuvant Treatment for Early Stage HER-2-positive Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-0346-0094-1_3openalex-snapshot
Trastuzumab Resistance in Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-0346-0094-1_4openalex-snapshot
Treatment with Trastuzumab Beyond Progression
inferred← citeshttps://doi.org/10.1007/978-3-319-28216-9_5openalex-snapshot
HER2-positive metastatic breast cancer: second-line treatment
inferred← citeshttps://doi.org/10.1007/978-3-319-70142-4_2openalex-snapshot
Resistance to HER2-Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-3-319-92633-9_5openalex-snapshot
Anti-angiogenesis
inferred← citeshttps://doi.org/10.1007/978-3-319-95228-4_19openalex-snapshot
Angiogenic Signaling Pathways and Anti-angiogenic Therapies in Human Cancer
inferred← citeshttps://doi.org/10.1007/978-3-540-28266-2_32openalex-snapshot
Targeting the HER Family of Receptors in the Treatment of Advanced Breast Cancer
inferred← citeshttps://doi.org/10.1007/978-3-540-28266-2_33openalex-snapshot
Biological Therapies for Metastatic Breast Cancer: Antiangiogenesis
inferred← citeshttps://doi.org/10.1007/978-3-540-31209-3_4openalex-snapshot
Targeting ERBB Receptors in Cancer
inferred← citeshttps://doi.org/10.1007/978-3-540-33177-3_33openalex-snapshot
Antiangiogenic Therapy for Normalization of Tumor Vasculature and Microenvironment
inferred← citeshttps://doi.org/10.1007/978-3-540-69743-5_20openalex-snapshot
HER2-Targeted Therapy
inferred← citeshttps://doi.org/10.1007/978-3-540-74386-6_2openalex-snapshot
Tumor Growth and Cell Proliferation
inferred← citeshttps://doi.org/10.1007/978-3-642-00475-9_2openalex-snapshot
Molecular Neurooncology and Neoangiogenesis of Malignant Gliomas
inferred← citeshttps://doi.org/10.1007/978-4-431-54409-8_19openalex-snapshot
Targeting Pro-Angiogenic TGF-β Signaling in the Tumor Microenvironment
inferred← citeshttps://doi.org/10.1007/978-90-481-3725-1_2openalex-snapshot
The Role of Oncogene Activation in Tumor Progression
inferred← citeshttps://doi.org/10.1007/978-94-007-5291-7_6openalex-snapshot
Possibilities of Targeted Therapies for Brain Metastasis
inferred← citeshttps://doi.org/10.1007/s00018-004-4277-7openalex-snapshot
Oncogenic protein tyrosine kinases
inferred← citeshttps://doi.org/10.1007/s00018-013-1331-3openalex-snapshot
Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?
inferred← citeshttps://doi.org/10.1007/s00018-014-1625-0openalex-snapshot
Developmental and pathological angiogenesis in the central nervous system
inferred← citeshttps://doi.org/10.1007/s00259-015-3062-1openalex-snapshot
99mTc-3PRGD2 SPECT to monitor early response to neoadjuvant chemotherapy in stage II and III breast cancer
inferred← citeshttps://doi.org/10.1007/s00262-008-0607-1openalex-snapshot
Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2/neu-positive tumour cells
inferred← citeshttps://doi.org/10.1007/s00280-005-0110-8openalex-snapshot
Trastuzumab: updates and future issues
inferred← citeshttps://doi.org/10.1007/s00280-008-0729-3openalex-snapshot
Her2/neu signaling blockade improves tumor oxygenation in a multifactorial fashion in Her2/neu+ tumors
inferred← citeshttps://doi.org/10.1007/s00280-015-2824-6openalex-snapshot
A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors
inferred← citeshttps://doi.org/10.1007/s00280-021-04303-4openalex-snapshot
UCP-2 inhibitor enhanced the efficacy of trastuzumab against HER2 positive breast cancer cells
inferred← citeshttps://doi.org/10.1007/s00330-003-2000-yopenalex-snapshot
Invasive breast cancer: correlation of dynamic MR features with prognostic factors
inferred← citeshttps://doi.org/10.1007/s00432-005-0022-3openalex-snapshot
Clinical significance of the quantitative assessment of the cytosolic concentration of HER-2/neu protein in breast cancer by immunoenzymatic assay (ELISA)
inferred← citeshttps://doi.org/10.1007/s00761-009-1648-6openalex-snapshot
Behandlung der Patientinnen mit HER2- (ErbB2-) positivem Mammakarzinom
inferred← citeshttps://doi.org/10.1007/s10147-024-02472-9openalex-snapshot
Plasma THBS1 as a predictive biomarker for poor prognosis and brain metastasis in patients with HER2-enriched breast cancer
inferred← citeshttps://doi.org/10.1007/s10330-010-0700-8openalex-snapshot
Mechanisms of resistance to trastuzumab: an updated review
inferred← citeshttps://doi.org/10.1007/s10334-004-0070-8openalex-snapshot
The C-neu mammary carcinoma in Oncomice; characterization and monitoring response to treatment with herceptin by magnetic resonance methods
inferred← citeshttps://doi.org/10.1007/s10456-010-9176-yopenalex-snapshot
Intravital microscopy in window chambers: a unique tool to study tumor angiogenesis and delivery of nanoparticles
inferred← citeshttps://doi.org/10.1007/s10456-018-9613-xopenalex-snapshot
Consensus guidelines for the use and interpretation of angiogenesis assays
inferred← citeshttps://doi.org/10.1007/s10549-016-3680-8openalex-snapshot
Trastuzumab improves tumor perfusion and vascular delivery of cytotoxic therapy in a murine model of HER2+ breast cancer: preliminary results
inferred← citeshttps://doi.org/10.1007/s10549-017-4310-9openalex-snapshot
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104)
inferred← citeshttps://doi.org/10.1007/s10549-018-4969-6openalex-snapshot
Comparative efficacy of adjuvant trastuzumab-containing chemotherapies for patients with early HER2-positive primary breast cancer: a network meta-analysis
inferred← citeshttps://doi.org/10.1007/s10555-012-9394-4openalex-snapshot
The impact of tumor microenvironment on cancer treatment and its modulation by direct and indirect antivascular strategies
inferred← citeshttps://doi.org/10.1007/s10555-022-10058-yopenalex-snapshot
Obesity and cancer—extracellular matrix, angiogenesis, and adrenergic signaling as unusual suspects linking the two diseases
inferred← citeshttps://doi.org/10.1007/s10620-012-2036-4openalex-snapshot
Suppression of the Epidermal Growth Factor Receptor Inhibits Epithelial–Mesenchymal Transition in Human Pancreatic Cancer PANC-1 Cells
inferred← citeshttps://doi.org/10.1007/s10637-005-2899-8openalex-snapshot
Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer
inferred← citeshttps://doi.org/10.1007/s10637-011-9696-3openalex-snapshot
Reversible posterior leukoencephalopathy syndrome and trastuzumab
inferred← citeshttps://doi.org/10.1007/s10637-012-9885-8openalex-snapshot
Phase I and pharmacokinetic study of pazopanib and lapatinib combination therapy in patients with advanced solid tumors
inferred← citeshttps://doi.org/10.1007/s10911-009-9116-xopenalex-snapshot
Stemming Resistance to HER-2 Targeted Therapy
inferred← citeshttps://doi.org/10.1007/s10989-005-9000-5openalex-snapshot
HER-2/neu Cancer Vaccines: Present Status and Future Prospects
inferred← citeshttps://doi.org/10.1007/s11307-016-0994-1openalex-snapshot
Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer
inferred← citeshttps://doi.org/10.1007/s11523-007-0062-5openalex-snapshot
Combining targeted therapies
inferred← citeshttps://doi.org/10.1007/s11523-018-0572-3openalex-snapshot
Low-Dose Continuous 5-Fluorouracil Combined with Leucovorin, nab-Paclitaxel, Oxaliplatin, and Bevacizumab for Patients with Advanced Pancreatic Cancer: A Retrospective Analysis
inferred← citeshttps://doi.org/10.1007/s11670-006-0083-0openalex-snapshot
Genistein inhibits expression of vascular endothelial growth factor in HER-2/neu transfected human breast cancer MCF-7 cells
inferred← citeshttps://doi.org/10.1007/s11670-007-0108-3openalex-snapshot
Growth inhibition of breast cancer in rat by AAV mediated angiostatin gene
inferred← citeshttps://doi.org/10.1007/s11864-007-0008-2openalex-snapshot
The Role of Trastuzumab in Early Stage Breast Cancer: Current Data and Treatment Recommendations
inferred← citeshttps://doi.org/10.1007/s11897-014-0193-9openalex-snapshot
Neuregulin-1 Signaling in the Pathogenesis of Chemotherapy-Induced Heart Failure
inferred← citeshttps://doi.org/10.1007/s11912-013-0359-8openalex-snapshot
New HER2-Positive Targeting Agents in Clinical Practice
inferred← citeshttps://doi.org/10.1007/s12032-025-02929-5openalex-snapshot
Detecting vascular normalization in epithelial ovarian cancer
inferred← citeshttps://doi.org/10.1007/s12094-012-0954-4openalex-snapshot
Safety and efficacy of metronomic non-pegylated liposomal encapsulated doxorubicin in heavily pretreated advanced breast cancer patients
inferred← citeshttps://doi.org/10.1007/s12254-008-0019-0openalex-snapshot
Adjuvant chemotherapy in breast cancer
inferred← citeshttps://doi.org/10.1007/s12609-010-0005-5openalex-snapshot
Antiangiogenesis Therapy in Breast Cancer
inferred← citeshttps://doi.org/10.1007/s12609-010-0037-xopenalex-snapshot
Targeted Therapies for HER2 Breast Cancer: A View of the Landscape
inferred← citeshttps://doi.org/10.1007/s13691-026-00885-zopenalex-snapshot
An exceptionally late and severe radiation recall dermatitis with chest-wall ulceration 32 years after breast radiotherapy: a case report and literature review
inferred← citeshttps://doi.org/10.1016/b978-0-12-374145-5.00333-8openalex-snapshot
Angiogenesis Signaling Pathways as Targets in Cancer Therapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-374419-7.00025-1openalex-snapshot
Molecular Biology of Breast Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-386456-7.05502-7openalex-snapshot
Modes of Neovascularization in Tumors and Clinical Translation of Antiangiogenic Therapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-387819-9.00029-3openalex-snapshot
References
inferred← citeshttps://doi.org/10.1016/b978-0-12-396521-9.00010-3openalex-snapshot
Inhibitors of Tumor Angiogenesis
inferred← citeshttps://doi.org/10.1016/b978-0-12-409547-2.12422-9openalex-snapshot
Peptide-Based Cancer Vaccines and Therapeutics for Solid Tumors Overexpressing HER-1, HER-2, HER-3, VEGF and IGF-1R
inferred← citeshttps://doi.org/10.1016/b978-0-12-416603-5.00013-4openalex-snapshot
Personalized Therapies for Cancer Treatment
inferred← citeshttps://doi.org/10.1016/b978-0-12-802761-5.00026-2openalex-snapshot
Molecular Biology of Breast Cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-816408-2.00002-6openalex-snapshot
Overexpression of antiapoptotic gene products and resistance to trastuzumab treatment of breast cancer
inferred← citeshttps://doi.org/10.1016/b978-0-12-821976-8.00009-8openalex-snapshot
Neurological complications of immunotherapy and monoclonal antibody therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00008-6openalex-snapshot
Tumor Microenvironment
inferred← citeshttps://doi.org/10.1016/b978-0-443-06694-8.50011-7openalex-snapshot
Vascular and Interstitial Biology of Tumors
inferred← citeshttps://doi.org/10.1016/b978-012160281-9/50009-8openalex-snapshot
The ErbB receptors and their role in cancer progression
inferred← citeshttps://doi.org/10.1016/b978-012369393-8/50005-5openalex-snapshot
MONOCLONAL ANTIBODY TO HER-2 IN BREAST CANCER
inferred← citeshttps://doi.org/10.1016/b978-012369448-5.50018-5openalex-snapshot
Inhibitors of tumor angiogenesis
inferred← citeshttps://doi.org/10.1016/b978-1-4557-2865-7.00008-4openalex-snapshot
Vascular and Interstitial Biology of Tumors
inferred← citeshttps://doi.org/10.1016/b978-343756420-8.50016-0openalex-snapshot
Komplementäre Therapieverfahren
inferred← citeshttps://doi.org/10.1016/j.addr.2005.11.002openalex-snapshot
Antibodies for angiogenesis inhibition, vascular targeting and endothelial cell transcytosis
inferred← citeshttps://doi.org/10.1016/j.addr.2011.09.007openalex-snapshot
How to improve exposure of tumor cells to drugs — Promoter drugs increase tumor uptake and penetration of effector drugs
inferred← citeshttps://doi.org/10.1016/j.addr.2017.06.011openalex-snapshot
Emerging strategies for delivering antiangiogenic therapies to primary and metastatic brain tumors
inferred← citeshttps://doi.org/10.1016/j.ajo.2008.09.022openalex-snapshot
The Inhibitory Effects of Trastuzumab on Corneal Neovascularization
inferred← citeshttps://doi.org/10.1016/j.bbadis.2022.166495openalex-snapshot
Biomechanical regulation of planar cell polarity in endothelial cells
inferred← citeshttps://doi.org/10.1016/j.bbrc.2003.08.128openalex-snapshot
Restoration of thrombospondin 1 expression in tumor cells harbouring mutant ras oncogene by treatment with low doses of doxycycline
inferred← citeshttps://doi.org/10.1016/j.bbrc.2004.11.053openalex-snapshot
ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter
inferred← citeshttps://doi.org/10.1016/j.bbrc.2005.06.123openalex-snapshot
Downregulation of the angiogenesis inhibitor thrombospondin 1 in fibroblasts exposed to platelets and their related phospholipids
inferred← citeshttps://doi.org/10.1016/j.bbrc.2009.04.118openalex-snapshot
A novel mouse monoclonal antibody targeting ErbB2 suppresses breast cancer growth
inferred← citeshttps://doi.org/10.1016/j.bcp.2009.05.027openalex-snapshot
Models for prevention and treatment of cancer: Problems vs promises
inferred← citeshttps://doi.org/10.1016/j.bcp.2024.116178openalex-snapshot
Influence of tumor microenvironment on the different breast cancer subtypes and applied therapies
inferred← citeshttps://doi.org/10.1016/j.biocel.2007.04.015openalex-snapshot
Molecular targeted therapies in breast cancer: Where are we now?
inferred← citeshttps://doi.org/10.1016/j.biochi.2013.08.021openalex-snapshot
n-3 polyunsaturated fatty acids and HER2-positive breast cancer: Interest of the fat-1 transgenic mouse model over conventional dietary supplementation
inferred← citeshttps://doi.org/10.1016/j.biologicals.2022.08.006openalex-snapshot
ADCC enhancement: A conundrum or a boon to mAb therapy?
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2015.12.016openalex-snapshot
3D scaffolds in breast cancer research
inferred← citeshttps://doi.org/10.1016/j.bioorg.2025.109140openalex-snapshot
The emerging role of Oxadiazole derivatives as VEGFR and EGFR inhibitors in Cancer therapy
inferred← citeshttps://doi.org/10.1016/j.breast.2004.08.019openalex-snapshot
Response of bilateral choroidal metastases of breast cancer to therapy with trastuzumab
inferred← citeshttps://doi.org/10.1016/j.canlet.2004.11.015openalex-snapshot
Antitumor activity of HER-2 inhibitors
inferred← citeshttps://doi.org/10.1016/j.canlet.2005.01.041openalex-snapshot
Herceptin: mechanisms of action and resistance
inferred← citeshttps://doi.org/10.1016/j.canlet.2008.03.008openalex-snapshot
Anti-angiogenic effect of 5-Fluorouracil-based drugs against human colon cancer xenografts
inferred← citeshttps://doi.org/10.1016/j.canlet.2008.04.045openalex-snapshot
Down regulation of c-Myc and induction of an angiogenesis inhibitor, thrombospondin-1, by 5-FU in human colon cancer KM12C cells
inferred← citeshttps://doi.org/10.1016/j.canlet.2010.02.002openalex-snapshot
Multiple molecular mechanisms underlying trastuzumab and lapatinib resistance in JIMT-1 breast cancer cells
inferred← citeshttps://doi.org/10.1016/j.canlet.2011.04.013openalex-snapshot
Trastuzumab has anti-metastatic and anti-angiogenic activity in a spontaneous metastasis xenograft model of esophageal adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.canlet.2014.10.046openalex-snapshot
Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.12.019openalex-snapshot
Metronomic chemotherapy for advanced breast cancer patients
inferred← citeshttps://doi.org/10.1016/j.canlet.2019.02.009openalex-snapshot
Squalamine blocks tumor-associated angiogenesis and growth of human breast cancer cells with or without HER-2/neu overexpression
inferred← citeshttps://doi.org/10.1016/j.ccell.2014.10.006openalex-snapshot
Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
inferred← citeshttps://doi.org/10.1016/j.ccell.2015.01.001openalex-snapshot
Emerging Strategies for Treating Brain Metastases from Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.ccr.2007.03.012openalex-snapshot
Bacterially Derived 400 nm Particles for Encapsulation and Cancer Cell Targeting of Chemotherapeutics
inferred← citeshttps://doi.org/10.1016/j.ccr.2007.08.029openalex-snapshot
Autocrine TNFα Signaling Renders Human Cancer Cells Susceptible to Smac-Mimetic-Induced Apoptosis
inferred← citeshttps://doi.org/10.1016/j.ccr.2008.12.011openalex-snapshot
Tumor-Associated Fibroblasts as “Trojan Horse” Mediators of Resistance to Anti-VEGF Therapy
inferred← citeshttps://doi.org/10.1016/j.cell.2023.08.043openalex-snapshot
The local microenvironment drives activation of neutrophils in human brain tumors
inferred← citeshttps://doi.org/10.1016/j.clbc.2011.03.018openalex-snapshot
Trastuzumab Emtansine (T-DM1): A Novel Agent for Targeting HER2+ Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2013.04.001openalex-snapshot
Current Status of Anti–Human Epidermal Growth Factor Receptor 2 Therapies: Predicting and Overcoming Herceptin Resistance
inferred← citeshttps://doi.org/10.1016/j.clbc.2015.06.001openalex-snapshot
Basal Protein Expression Is Associated With Worse Outcome and Trastuzamab Resistance in HER2+ Invasive Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.clbc.2018.09.010openalex-snapshot
Metastatic Breast Cancer Patient With Activating HER2 Exon 20 Insertion Mutation With Response to Poziotinib: Case Report of Compassionate Drug Use
inferred← citeshttps://doi.org/10.1016/j.clinthera.2009.08.005openalex-snapshot
Anthracycline- and/or taxane-resistant breast cancer: Results of a literature review to determine the clinical challenges and current treatment trends
inferred← citeshttps://doi.org/10.1016/j.cma.2022.115484openalex-snapshot
Optimizing combination therapy in a murine model of HER2+ breast cancer
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2003.08.004openalex-snapshot
Tyrosine kinase receptors as attractive targets of cancer therapy
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2009.11.003openalex-snapshot
Brain metastases in HER2-positive breast cancer: The evolving role of lapatinib
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2010.09.002openalex-snapshot
Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2009.06.007openalex-snapshot
Trastuzumab versus lapatinib: The cardiac side of the story
inferred← citeshttps://doi.org/10.1016/j.ctrv.2012.04.008openalex-snapshot
Current approaches and future directions in the treatment of HER2-positive breast cancer
inferred← citeshttps://doi.org/10.1016/j.ctrv.2012.05.006openalex-snapshot
Therapeutic approaches for HER2-positive brain metastases: Circumventing the blood–brain barrier
inferred← citeshttps://doi.org/10.1016/j.ctrv.2014.06.002openalex-snapshot
Metronomic therapy and breast cancer: A systematic review
inferred← citeshttps://doi.org/10.1016/j.drup.2003.12.004openalex-snapshot
Targeting hypoxia tolerance in cancer
inferred← citeshttps://doi.org/10.1016/j.drup.2005.06.002openalex-snapshot
New approaches to reverse resistance to hormonal therapy in human breast cancer
inferred← citeshttps://doi.org/10.1016/j.ejca.2004.07.031openalex-snapshot
Circulating biomarkers from tumour bulk to tumour machinery: promises and pitfalls
inferred← citeshttps://doi.org/10.1016/j.ejca.2005.03.021openalex-snapshot
Gefitinib–trastuzumab combination on hormone-refractory prostate cancer xenograft
inferred← citeshttps://doi.org/10.1016/j.ejca.2008.09.013openalex-snapshot
Her2-positive breast cancer: Herceptin and beyond
inferred← citeshttps://doi.org/10.1016/j.ejso.2005.05.015openalex-snapshot
Endothelial adhesion molecules in breast cancer invasion into the vascular and lymphatic systems
inferred← citeshttps://doi.org/10.1016/j.fct.2010.05.052openalex-snapshot
Flaxseed oil–trastuzumab interaction in breast cancer
inferred← citeshttps://doi.org/10.1016/j.gene.2024.148607openalex-snapshot
Emerging trends and therapeutic applications of monoclonal antibodies
inferred← citeshttps://doi.org/10.1016/j.gmit.2013.07.001openalex-snapshot
Her-2/neu overexpression is associated with thrombospondin-1-related angiogenesis and thrombospondin-1-unrelated lymphangiogenesis in breast cancer
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e24670openalex-snapshot
Metronomic chemotherapy and drug repurposing: A paradigm shift in oncology
inferred← citeshttps://doi.org/10.1016/j.heliyon.2024.e28923openalex-snapshot
Significant effect of posterior line treatment of HER2 positive advanced gastric cancer: A case report
inferred← citeshttps://doi.org/10.1016/j.humpath.2003.05.003openalex-snapshot
A case of metastatic breast cancer with outgrowth of HER2-negative cells after eradication of HER2-positive cells by humanized Anti-HER2 monoclonal antibody (trastuzumab) combined with docetaxel
inferred← citeshttps://doi.org/10.1016/j.imlet.2007.12.001openalex-snapshot
ErbB-directed immunotherapy: Antibodies in current practice and promising new agents
inferred← citeshttps://doi.org/10.1016/j.jaad.2009.05.052openalex-snapshot
Angiogenesis in cutaneous disease: Part I
inferred← citeshttps://doi.org/10.1016/j.jamcollsurg.2017.08.023openalex-snapshot
Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
inferred← citeshttps://doi.org/10.1016/j.jconrel.2010.04.009openalex-snapshot
The role of HER2 in cancer therapy and targeted drug delivery
inferred← citeshttps://doi.org/10.1016/j.jconrel.2014.12.018openalex-snapshot
Improving drug delivery to solid tumors: Priming the tumor microenvironment
inferred← citeshttps://doi.org/10.1016/j.jconrel.2017.04.029openalex-snapshot
Nucleic acid combinations: A new frontier for cancer treatment
inferred← citeshttps://doi.org/10.1016/j.mehy.2006.10.065openalex-snapshot
Potential therapeutic implications of intracrine angiogenesis
inferred← citeshttps://doi.org/10.1016/j.molimm.2020.01.009openalex-snapshot
A new anti-HER2 antibody that enhances the anti-tumor efficacy of trastuzumab and pertuzumab with a distinct mechanism of action
inferred← citeshttps://doi.org/10.1016/j.molonc.2007.01.003openalex-snapshot
Cancer therapeutic antibodies come of age: Targeting minimal residual disease
inferred← citeshttps://doi.org/10.1016/j.mvr.2007.05.003openalex-snapshot
Tumor microvasculature and microenvironment: Targets for anti-angiogenesis and normalization
inferred← citeshttps://doi.org/10.1016/j.mvr.2013.04.009openalex-snapshot
Microvascular morphometrics of the hypophysis and pituitary tumors: From bench to operating theatre
inferred← citeshttps://doi.org/10.1016/j.nano.2006.12.002openalex-snapshot
Nanotechnology platforms and physiological challenges for cancer therapeutics
inferred← citeshttps://doi.org/10.1016/j.neo.2018.10.008openalex-snapshot
Characterizing Trastuzumab-Induced Alterations in Intratumoral Heterogeneity with Quantitative Imaging and Immunohistochemistry in HER2+ Breast Cancer
inferred← citeshttps://doi.org/10.1016/j.pathog.2015.05.002openalex-snapshot
HER2: An emerging biomarker in non-breast and non-gastric cancers
inferred← citeshttps://doi.org/10.1016/j.pep.2021.106004openalex-snapshot
Evaluating the efficacy of immobilized metal affinity chromatography (IMAC) for host cell protein (HCP) removal from anti-HER2 scFv expressed in Escherichia coli
inferred← citeshttps://doi.org/10.1016/j.prp.2023.154917openalex-snapshot
Immunoexpression of HER2 pathway related markers in HER2 invasive breast carcinomas treated with trastuzumab
inferred← citeshttps://doi.org/10.1016/j.semcancer.2003.09.014openalex-snapshot
Oncogenes and tumor angiogenesis
inferred← citeshttps://doi.org/10.1016/j.semcancer.2008.03.013openalex-snapshot
Unraveling the microenvironmental influences on the normal mammary gland and induction and progression of breast cancer
inferred← citeshttps://doi.org/10.1016/j.suronc.2008.11.001openalex-snapshot
Herceptin and breast cancer: An overview for surgeons
inferred← citeshttps://doi.org/10.1016/j.tibtech.2013.10.004openalex-snapshot
The potential legacy of cancer nanotechnology: cellular selection
inferred← citeshttps://doi.org/10.1016/j.tranon.2014.09.011openalex-snapshot
Evaluating treatment response using DW-MRI and DCE-MRI in trastuzumab responsive and resistant HER2-overexpressing human breast cancer xenografts
inferred← citeshttps://doi.org/10.1016/j.uct.2006.05.001openalex-snapshot
Antibodies and antibody-fusion proteins as anti-angiogenic, anti-tumor agents
inferred← citeshttps://doi.org/10.1016/j.xcrm.2024.101626openalex-snapshot
Modulating cancer mechanopathology to restore vascular function and enhance immunotherapy
inferred← citeshttps://doi.org/10.1016/j.yexcr.2007.03.042openalex-snapshot
Intra- and extracellular signaling by endothelial neuregulin-1
inferred← citeshttps://doi.org/10.1016/j.yexcr.2008.08.015openalex-snapshot
The role of Neuregulin-1β/ErbB signaling in the heart
inferred← citeshttps://doi.org/10.1016/j.yexcr.2010.01.009openalex-snapshot
Mechanisms of resistance to HER family targeting antibodies
inferred← citeshttps://doi.org/10.1016/j.yjmcc.2008.02.278openalex-snapshot
ErbB receptors, their ligands, and the consequences of their activation and inhibition in the myocardium
showing the first 200 of 576
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.